Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 STA, Regulus Enter Collaboration | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

STA, Regulus Enter Collaboration

For oligonucleotide synthesis research and mid-scale non-GMP/cGMP manufacturing

By: Betsy Louda

, Contract Pharma

STA Pharmaceutical Co., a WuXi AppTec group company, and Regulus Therapeutics have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.

 

Under the agreement, STA will become a new strategic development and manufacturing partner for Regulus’ preclinical and clinical programs of microRNA-targeting drugs used to treat a broad range of diseases. Regulus will provide STA with expertise, technical know-how, and training in the field of oligonucleotide scale-up.

 

STA recently established oligonucleotide R&D labs at both its facilities in San Diego, California and Changzhou, China. The state-of-the-art oligonucleotide GMP manufacturing facility at Changzhou will become operational later this year.

 

“We are excited to establish a high quality oligonucleotide R&D and manufacturing technology and capability platform, and it’s a great honor to work with an innovative, pioneering company, such as Regulus. This partnership will allow STA to expedite Regulus’ oligonucleotide therapeutics programs into the clinic, and eventually, to patients,” said Dr. Minzhang Chen, chief executive officer of STA Pharmaceutical. 

 

“By partnering with a well-respected, world-class organization like WuXi STA, we gain their commitment to support our long-term development and commercialization goals,” said Jay Hagan, president and chief executive officer of Regulus.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics